New Stock First Day | Yiming Angke-B Debuts on the Market with a High Opening of 13.98% in the Morning Session
Yimingang Technology-B made its debut on the stock market. According to the announcement, the company issued approximately 17.1472 million shares at a price of HKD 18.60 per share, with a board lot size of 200 shares. The net proceeds amounted to approximately HKD 233.4 million. As of the time of writing, the stock has risen by 13.98% to HKD 21.2, with a trading volume of HKD 4.6257 million.
According to Dolphin Research APP, Yimingangke-B (01541) has made its debut on the stock market. The announcement shows that the company has issued approximately 17.1472 million shares at a price of HKD 18.60 per share, with a board lot size of 200 shares. The net proceeds amount to approximately HKD 233.4 million. As of the time of writing, the stock has risen by 13.98% to HKD 21.2, with a turnover of HKD 4.6257 million.
It is reported that Yimingangke is committed to the development of tumor immunotherapy. Its core product, IMM01 (an innovative CD47-targeting molecule in the clinical stage), is included in its product pipeline. The pipeline consists of 14 candidate drugs, characterized by a comprehensive asset portfolio based on innate immunity and targeting CD47 and other novel immune checkpoints, including IMM01. Among them, eight clinical projects are currently underway.
In addition, the company's product pipeline also includes ten other candidate drugs targeting key innate and adaptive immune targets at different stages of development, including CD24 antibodies, CD24-targeting bispecific molecules, and three adaptive immune drugs in clinical and IND stages.